Trial record 8 of 10 for:    aastrom

Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Aastrom Biosciences
ClinicalTrials.gov Identifier:
NCT01020968
First received: November 25, 2009
Last updated: January 20, 2014
Last verified: January 2014

November 25, 2009
January 20, 2014
December 2009
March 2014   (final data collection date for primary outcome measure)
Incidence of major adverse cardiac event (MACE) (MACE defined as: cardiac death, cardiac arrest, myocardial infarction, sustained ventricular arrhythmias, pulmonary edema, acute heart failure, unstable angina and major bleeding) [ Time Frame: Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01020968 on ClinicalTrials.gov Archive Site
  • Left ventricular ejection fraction (LVEF) (As determined by Echo, Cardiac CT and SPECT) [ Time Frame: Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12. CT and SPECT are only assessed at Baseline and Month 6. ] [ Designated as safety issue: No ]
  • Change in LV and RV dimensions and in LV volumes (As determined by Echo, Cardiac CT and SPECT) [ Time Frame: Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12. CT and SPECT are only assessed at Baseline and Month 6. ] [ Designated as safety issue: No ]
  • Wall Motion Score Index (WMSI) (As determined by Echo, Cardiac CT and SPECT) [ Time Frame: Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12. CT and SPECT are only assessed at Baseline and Month 6. ] [ Designated as safety issue: No ]
  • Assessment of myocardial perfusion in ischemic patient cohort, only (As determined by SPECT) [ Time Frame: Baseline and Month 3 ] [ Designated as safety issue: No ]
  • Exercise tolerance (6 minute walk test) [ Time Frame: Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 ] [ Designated as safety issue: No ]
  • Heart failure status (As determined by New York Heart Association (NYHA) heart failure status (NYHA) class and Brain Natriuretic Peptide [BNP]) [ Time Frame: Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 ] [ Designated as safety issue: No ]
  • Angina status (As determined by Canadian Cardiovascular Society (CCS) classification and Troponin I Levels) [ Time Frame: Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 ] [ Designated as safety issue: No ]
  • Quality of life (As determined by Minnesota Living with Heart Failure Questionnaire [MLHFQ]) [ Time Frame: Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 ] [ Designated as safety issue: No ]
  • Pulmonary function (As determined by metabolic stress test) [ Time Frame: Baseline, Month 6 and Month 12 ] [ Designated as safety issue: No ]
  • Device implantation, transplantation and positive inotrope use (As determined by incidence rates) [ Time Frame: Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 ] [ Designated as safety issue: No ]
  • AICD firing rate [ Time Frame: Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 ] [ Designated as safety issue: No ]
  • Changes in medication for heart failure [ Time Frame: Outcome measures will generally be assessed at Baseline, Month 3, Month 6 and Month 12 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
Catheter-based Transendocardial Delivery of Autologous Bone Marrow-Derived Cells in Patients With Heart Failure Due to Dilated Cardiomyopathy

This study is designed to assess the safety profile and the efficacy of cardiac repair cells (CRCs) administered via catheter in treating patients with dilated cardiomyopathy (DCM).

Heart failure remains a major public health problem, affecting 5 million patients in the US, with 550,000 new diagnoses made each year (Hunt SA; et al., 2005). Heart failure is the leading cause of hospitalization in persons over 65 years of age with cost exceeding $29 billion annually. Prognosis is very poor once a patient has been hospitalized with heart failure. The mortality risk after heart failure hospitalization is 11.3% at 30 days, 33.1% at 1 year and well over 50% within 5 years (Hunt SA; et al., 2005). These numbers emphasize the need to develop and implement more effective treatments to manage heart failure.

Aastrom is targeting a subset of heart failure patient population, namely those diagnosed with dilated cardiomyopathy. The World Health Organization (WHO) defines dilated cardiomyopathy (DCM) as a cardiac condition wherein a ventricular chamber exhibits increased diastolic and systolic volume and a low (<40%) ejection fraction (Manolio TA; et al., 1992; Towbin JA; et al., 2006). DCM is reported to affect 108,000 to 150,000 patients in the United States (Richardson P; et al., 1996; Towbin JA; et al., 2006).

This study is a prospective, stratified, randomized, open-label, controlled, multi-center study to assess the safety profile and the efficacy of CRCs administered via catheter in treating patients with DCM. Two strata will be used: ischemic (IDCM) and non-ischemic (NIDCM). Within each stratum, patients will be randomized to receive either CRC treatment or control in a 2:1 ratio (8 patients per CRC treatment group and 4 patients per control group). It will enroll a total of 24 patients at 2 sites in the U.S.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Dilated Cardiomyopathy
Biological: Cardiac Repair Cells (CRCs)
CRCs will be administered via catheter-based injection to the endocardial surface of the left ventricle.
Other Name: autologous bone marrow cells
  • Experimental: Treatment
    The Treatment arm of the study will receive standard of care therapy, a bone marrow aspiration and catheter-based injections of the study cellular product.
    Intervention: Biological: Cardiac Repair Cells (CRCs)
  • No Intervention: Control
    Standard-of-care therapy will be provided for DCM condition only. Patients in this group may be offered the opportunity to receive CRC treatment in a separate open-label cross-over protocol after completing at least 6 months of treatment. However, before a cross-over protocol becomes available, an independent data and safety monitoring board (DSMB), the FDA and the Sponsor will review 6-month safety and efficacy data from the first 10 CRC-treated patients and the risk-benefit profile in order to assess the value and utility of such a protocol. If a cross-over protocol becomes available, the investigators will assess the status of an individual control patient, discuss the cross-over option with the patient, and will ensure that the patient meets the eligibility criteria of the cross-over protocol in order to qualify for CRC treatment.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
24
March 2014
March 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of ischemic or non-ischemic dilated cardiomyopathy according to WHO criteria. Ischemic: DCM in a patient with a history of myocardial infarction or evidence of clinically significant (>/= 70% narrowing of a major epicardial artery) coronary artery disease. Non-ischemic: Dilation and impaired contraction of left ventricle or both ventricles of idiopathic, familial/genetic, viral and/or immune, toxic origin, or associated with recognized cardiovascular disease in which the degree of myocardial dysfunction is not explained by normal loading conditions or the extent of ischemic damage.
  • No other cardiac surgery or percutaneous cardiac interventions likely to produce clinical improvement, as determined by an interventional cardiologist (for PTCA) and a cardiothoracic surgeon (for CABG). This condition is satisfied in patients w/chronic ischemic disease who have previously been successfully revascularized but have failed to show clinical improvement. All patients who are candidates for revascularization are ineligible for participation.
  • LVEF </= 30% by echocardiogram within 30 days prior to randomization.
  • Symptomatic heart failure in NYHA class III or IV.
  • Able to comply with scheduled visits in cardiac out-patient clinic.
  • Able to tolerate study procedures, including bone marrow aspiration, cardiac CT, metabolic stress test,6 minute walk test.
  • Males and females, 18-86 years of age.
  • Life expectancy of 6 months or more in the opinion of the investigator.
  • Able to give informed consent.
  • Normal organ and marrow function (Leukocytes >/= 3,000/microgram, Absolute neutrophil count >/= 1,500/microgram, Platelets >/= 140,000/microgram, AST(SGOT)/ALT (SGPT) </= 2.5 X institutional standards range and Creatinine </= 2.5 mg/dL).
  • Controlled blood pressure (systolic blood pressure </= 140; diastolic blood pressure </= 90 mmHg) and established anti-hypertensive therapy as necessary prior to entry into the study.
  • Stable, standard medical therapy for DCM for at least 1 month with NO new medications to treat the disease introduced in the last 3 months. Standard medical therapy includes: Placement of AICD unless contraindicated (refusal of AICD not considered valid contraindication), use of ACE inhibitors and/or AT-1 receptor blockers as well as loop diuretics unless contraindicated and, depending on the type of heart failure associated with the disease, standard therapy may also include use of vasodilators, beta blockers, digoxin, and aldosterone or other medications.
  • Pre-existing conditions are adequately controlled in the opinion of the investigator.
  • Fertile patients must agree to use an appropriate form of contraception while participating in the study.

Exclusion Criteria:

  • Severe primary valvular heart disease including, but not limited to, aortic valve stenosis and insufficiency.
  • Known history of COPD defined as Gold stage IIB (FEV1/FVC<70% with 30%</=FEV1<50% predicted, with or without chronic symptoms of cough, sputum production, dyspnea) or more severe or restrictive pulmonary disease.
  • Known history of primary pulmonary hypertension.
  • VAD implantation.
  • Myocardial infarction within 4 weeks prior to randomization.
  • History of life-threatening ventricular arrhythmia, except if an AICD is implanted.
  • Unstable angina, characterized by increasingly frequent episodes with modest exertion or at rest, worsening severity, and prolonged duration.
  • Patients at high risk for complications due to injection procedure (e.g. patients who have severe peripheral atherosclerotic disease that does not allow advancement of the catheter; patients who have a prosthetic aortic or mitral valve; patients who have a LV thrombus or aneurysm; patients who have an aortic dissection or aneurysm, etc.).
  • Patients w/poorly controlled diabetes mellitus (HbAlc>9.0%).
  • Patients receiving treatment with hematopoietic growth factors (e.g. EPO, G-CSF).
  • Patients who require uninterruptible anticoagulation therapy (e.g. warfarin)that cannot be stopped for 72 hours prior to bone marrow aspiration and intramyocardial injections; OR patients receiving anti-platelet therapy (e.g. clopidogrel) that cannot be stopped for 7 days prior to bone marrow aspiration and transendocardial injections, unless contraindicated.
  • Known cancer and undergoing treatment including chemotherapy and radiation.
  • Patients requiring continuous, systemic, high dose corticosteroid therapy (more than 7.5 mg/day) within 1 month before aspiration or 6 months after injection procedure.
  • End stage renal disease requiring dialysis.
  • Patients pregnant or lactating; positive for hCG
  • History of alcohol consumption regularly exceeding the equivalent of 2 drinks/day (1 drink = 5 oz of wine or 12 oz [360mL] of beer or 1.5 oz [45mL]) of hard liquor or history of illicit drug use w/in 6 months of screening.
  • Known allergies to protein products (horse or bovine serum, or porcine trypsin) used in the ex-vivo cell production process.
  • BMI of 40 Kg/m2 or greater.
  • Patients receiving experimental medications or participating in another clinical study within 30 days of screening.
  • HIV or syphilis, positive at time of screening.
  • Active Hepatitis B or Hepatitis C infection at the time of screening.
  • Patient determined unsuitable for cellular therapy, in the opinion of the investigator or sponsor.
  • Patients receiving anti-angiogenic drugs (e.g. anti-VEGF).
  • Known allergy or sensitivity to contrast agents used in imaging procedures.
  • Minimum LV wall thickness of less than 6mm as determined by ECHO.
Both
18 Years to 86 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01020968
ABI-55-0811-1
Yes
Aastrom Biosciences
Aastrom Biosciences
Not Provided
Principal Investigator: Timothy Henry, MD Minneapolis Heart Institute Foundation
Aastrom Biosciences
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP